SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

11 Feb 2026 Evaluate
The sales declined to Rs. 1646.81 millions for the December 2025 quarter as compared to Rs. 1795.94 millions during the corresponding quarter last year.Net profit declined -11.61% to Rs. 186.07 millions from Rs. 210.51 millions.Operating profit for the quarter ended December 2025 decreased to 370.82 millions as compared to 373.94 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 1646.81 1795.94 -8.30 5182.70 5112.03 1.38 6672.05 6054.60 10.20
Other Income 102.32 116.61 -12.25 466.70 285.95 63.21 362.16 335.01 8.10
PBIDT 370.82 373.94 -0.83 1243.05 1047.10 18.71 1278.02 1406.68 -9.15
Interest 14.75 6.68 120.81 93.02 52.84 76.04 65.84 58.06 13.40
PBDT 330.93 367.26 -9.89 1124.89 994.26 13.14 1212.18 937.76 29.26
Depreciation 78.02 69.57 12.15 231.79 196.13 18.18 270.47 235.19 15.00
PBT 252.91 297.69 -15.04 893.10 798.13 11.90 941.71 702.57 34.04
TAX 66.84 87.18 -23.33 248.58 222.98 11.48 252.03 196.13 28.50
Deferred Tax -8.38 -15.53 -46.04 -66.23 -37.45 76.85 -47.89 -75.49 -36.56
PAT 186.07 210.51 -11.61 644.52 575.15 12.06 689.68 506.44 36.18
Equity 105.79 105.37 0.40 105.79 105.37 0.40 105.37 104.69 0.65
PBIDTM(%) 22.52 20.82 8.15 23.98 20.48 17.09 19.15 23.23 -17.55

Bliss GVS Pharma Share Price

258.65 4.35 (1.71%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×